We have hypothesized that the expression and/or DNA methylation of LTB4R/LTB4R2 genes might be promising prognostic and predictive markers useful in developing individualized therapy with leukotriene receptor inhibitors for malignant tumors, including BC. The gene discussed is LTB4R2; the disease is breast cancer.